Otras Aventuras de los Farmas USA

GRF

Y con esto hasta que cierre usa y eche un ojo a lo que llevo paro, estoy muy cansado hoy.

uy ni me habia dado cuenta, gracias. tomo nota. 

Lo llevas diciendo varios días.
Igual hay que descansar un poco más..

No lo sabes bien , llevo un ritmo frenético. 

Durmiendo 5h al día y todo el día delante de un ordenador.....qué ganas tengo de que el mercado me dé la oportunidad de liquidar SOLO y SNOW y tomarme un respiro.

Hora de NIO y SRPT.
Voy a cenar algo. 

https://seekingalpha.com/pr/18213081-fibrogen-reports-fourth-quarter-and-full-year-2020-financial-results

FGEN
-18% ahora mismo

today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will hold an advisory committee (AdCom) meeting to review the new drug application for roxadustat in the U.S. The companies have not received a confirmed AdCom meeting date from the FDA.

FibroGen (NASDAQ:FGEN) reported quarterly losses of $(0.64) per share. This is a 42.86 percent increase over losses of $(1.12) per share from the same period last year. The company reported $65.00 million in sales this quarter. This is a 715.15 percent increase over sales of $7.97 million the same period last year

Edito: qué manera de intentar tangar al personal. Dentro 41.21 

Total revenue for the fourth quarter of 2020 was $65.0 million, as compared to $8.0 million for the fourth quarter of 2019. The current quarter revenue consists of net product revenues of $29.2 million for roxadustat sales in China, $21.5 million in development revenue, and $14.3 million in license revenue related to NDD approval in Japan. Total net roxadustat sales in China for 2020 were $72.5 million.

Net loss for the fourth quarter of 2020 was $58.6 million, or $0.64 net loss per basic and diluted share, compared to a net loss of $98.1 million, or $1.12 net loss per basic and diluted share one year ago.

Net loss for the year was $189.3 million, or $2.11 net loss per basic and diluted share, compared to a net loss of $77.0 million, or $0.89 net loss per basic and diluted share one year ago.

At December 31, 2020, FibroGen had $732.1 million in cash, restricted time deposits, cash equivalents, investments, and receivables.

Based on our latest forecast, we estimate our 2021 ending cash to be in the range of $660 to $670 million.

Repaso.

SNOW- Le veo opciones de que llegue a los 287 pero teniendo el ER el miércoles y tras el susto de la semana pasada, en cuanto se me ponga a tiro, si es que se pone, la liquido.

SOLO- Similar a Snow parece que han rebotado en sitio que tenían que rebotar, han roto la primera bajista pero.....ni un pelo me fio.  Además que echando cálculos la semana pasada me costó -1.000€ entre las amputaciones que hice.